Study Compares Impact of Two Therapies on Survival in Squamous Cell Carcinoma
Survival rates in patients with cSCC receiving high-dose chemoradiotherapy vs conventional radical surgery were compared.
Is NIFTP Truly a Non–Thyroid Cancer Diagnosis?
According to the American Thyroid Association guidelines, noninvasive follicular thyroid neoplasm with papillary-like features is benign.
Assessing Quality of Life After Thyroidectomy
Researchers evaluated the incidence of physical, psychological, and lifestyle effects among patients with differentiated thyroid cancer.
The Microbiome and Colorectal Cancer: Current Clinical Trials
Here, we look at the currently open and recruiting clinical trials that focus on the role of the microbiome in colorectal cancer.
Trends in the Management of Non-Melanoma Skin Cancers
A recent review article highlighted developments in the treatment of non-melanoma skin cancers, from new chemoprevention agents to telemedicine.
Is Indoor Tanning Linked to Melanoma and Non-Melanoma Skin Cancers?
A new meta-analysis offers compelling evidence on the causal relationship between indoor tanning and skin cancer risk.
Key Advances in Oncology, 2018
Our team reviews the most important advances in oncology in 2018, including those in breast cancer, hematologic cancers, lung cancer, immunotherapy, and more.
Oncology Conference Highlights, Q4
Our team reviews 2018 conference highlights in oncology care, including studies from ASH, SABCS, and SIO.
Researchers ID Common Terminology to Describe Non-Melanoma Skin Cancers
The findings of a systematic review may help standardize reflectance confocal microscopy terminology, which is used to describe non-melanocytic lesions.
Hope for New Apoptotic Regulatory Pathway in Treating Non-Melanoma Skin Cancers
Researchers studied whether the mechanistic target of mTORC2 directs UVB–induced apoptosis by regulating the expression of NOXA downstream of FOXO3a.
Three Key Messages to Guide the Success of Oncology Biosimilars
The authors of a European review provide recommendations for all stakeholders on smooth implementation of cancer biosimilar agents.
The Role of Biosimilars in Value-Based Oncology Care
Can expanded use of oncology biosimilar agents and supportive care agents help support the CMS' value-based care efforts?
Sizing Up Ultrasound-Based Risk-Stratification Systems for Thyroid Nodules
The performance of three international guidelines in detecting thryoid cancer was compared based on their sensitivity and fine-needle aspiration rates.
Promising New Prognostic Score for High-Risk DLBCL
Researchers compared the ability of a novel prognostic score vs existing scores to identify patients with high-risk DLBCL.
Top Discoveries in Chronic Lymphocytic Leukemia at ASH 2018
In an interview with Cancer Network, Brad S. Kahl, MD, weighs in on the top CLL research presented at ASH 2018 in San Diego.
TRIM29: A New Target in Treatment of Squamous Cell Carcinoma?
A new study in Cancer Research evaluated the function of TRIM29 in regulating keratin distribution and migration/invasion of SCC.
Do Larger Thyroid Tumors Mean Higher Rates of Malignancy and False-Negative FNA Results?
The authors looked at whether rates of malignancy and false-negative fine-needle aspiration results are heightened in large thyroid nodules.
Comparing Field Treatment for Actinic Keratosis
Researchers evaluated the efficacy of 5-florouracil vs imiquimod in preventing site-specific keratinocyte carcinoma.
Novel Immunotherapy for Primary Hemophagocytic Lymphohistiocytosis
Results of a study evaluating the safety and efficacy of a promising new agent were presented at ASH 2018.
Can Venetoclax Plus R-CHOP Improve Outcomes in Aggressive DLBCL?
In the single-arm, multicenter, phase II part of the CAVALLI trial, the researchers analyzed the efficacy of 800-mg venetoclax plus R-CHOP in all first-line DLBCL patients.
Impact of Checkpoint Blockade Therapy on Subsequent Treatment in Non-Hodgkin Lymphoma Patients
Research presented at ASH 2018 examined whether checkpoint blockade therapy sensitizes patients with relapsed/refractory NHL to consequent treatment.
Acquired Mutation in BCL2 Confers Resistance to Tx in Progressive CLL
Researchers analyzed a new recurrent BCL2 mutation appearing in a cohort of patients with CLL-type progressions treated with venetoclax.
Does Adding Daratumumab Benefit Transplant-Ineligible Myeloma Patients?
Researchers examined adding daratumumab to standard of care in newly diagnosed transplant-ineligible myeloma patients.
Uncovering Novel Data on Myeloma Patients Treated With Proteasome Inhibitors
Researchers uncovered distinct clinical characteristics in relapsed/refractory multiple myeloma patients receiving proteasome inhibitors.
New Combo Therapy Shows Promise in Leukemia
Leukemia cells show sensitivity to restriction of BCL2 and BTK with the combination of venetoclax and ibrutinib.
Using Clonal Hematopoiesis to Assess Risk in Lymphoma Patients
Researchers studied clonal hematopoiesis of indeterminate potential (CHIP) as a way to assess risk for increased mortality in lymphoma patients.
A Better Risk Model for DLBCL Patients?
Researchers developed an enhanced genomic model combining clinical factors and select gene mutations in order to better predict survival in patients with DLBCL who were administered first-line R-CHOP.
Single or Double Autologous Transplantation in New Myeloma Cases?
Researchers analyzed double vs single autologous stem cell transplantation in patients with newly diagnosed multiple myeloma, after previous conflicting results.
Early Intervention With New Drug Combo Beneficial in Myeloma?
This study looked at the benefit of early therapeutic intervention with the combination of elotuzumab, lenalidomide, and dexamethasone in patients with high-risk smoldering multiple myeloma.
Allogeneic Transplantation in Elderly AML Patients
Allogeneic hematopoietic stem cell transplantation could improve outcomes of elderly patients with acute myeloid leukemia.